Controlling cancer by restricting arginine availability--arginine-catabolizing enzymes as anticancer agents

Anticancer Drugs. 2004 Oct;15(9):825-33. doi: 10.1097/00001813-200410000-00002.

Abstract

Interest has recently been revived in enzymes that degrade essential amino acids. Arginine-catabolizing enzymes now predominate and are discussed in this review. Apart from reducing tumor load through cell death occurring as a result of deprivation alone, these catabolic enzymes conveniently leave the remaining malignant cells vulnerable to other therapeutic modalities through combinatorial treatments with cycle-dependent drugs, the timing of additional treatment after deprivation being crucial.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / therapeutic use*
  • Arginase / metabolism*
  • Arginase / pharmacology
  • Arginase / therapeutic use*
  • Arginine / antagonists & inhibitors
  • Arginine / deficiency
  • Arginine / metabolism*
  • Carboxy-Lyases / metabolism
  • Carboxy-Lyases / therapeutic use
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Neoplasms / metabolism

Substances

  • Antineoplastic Agents
  • Arginine
  • Arginase
  • Carboxy-Lyases
  • arginine decarboxylase